Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Next Previous
Trial Profile

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon; Retifanlimab
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASTRO-VAC CNS; BRIA-ABC
  • Sponsors BriaCell Therapeutics Corp

Most Recent Events

  • 24 Jun 2025 According to a BriaCell Therapeutics Corp media release, the independent Data Safety Monitoring Board (DSMB) has completed its third scheduled safety data review. Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications.
  • 02 Jun 2025 According to a BriaCell Therapeutics Corp media release, trial in progress data form this trial presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 23 May 2025 According to a BriaCell Therapeutics Corp media release, data from this study will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company look forward to confirming results in ongoing pivotal Phase 3 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top